Drug-resistant bacteria can be treated by certain polypeptide

Medical and health workers may soon be able to develop a drug for refractory abscess bacteria, because these bacteria almost sent about tens of thousands of people to the emergency room.

Researchers from the University of Columbia in British have used a peptide, or a substance called miniprotein, to successfully stop drug-resistant bacteria from producing abscesses or purulent lesions through recombinant human proteins. Such polypeptide impedes their secretion by interfering with the stress response of the bacteria.

Abscess is bacterial-mediated tissue lesion that causes about 3.2 million people to enter the emergency room each year. The reason for this is that these bacteria are resistant to antibiotics and can only be treated by reducing infection and pyogen.

Microbiology professor Bob Hancock at Columbia University said, "Abscesses can happen almost anywhere in the body, and antibiotics are usually ineffective. While the use of polypeptides gives us a new way of thinking, because its mechanism is completely different to that of antibiotics."

Hancock and his colleagues found that the bacteria in the abscess showed a state of stress growth. They used a synthetic peptide called DJK-5 to interfere with the stress response of the bacteria, thus achieving the effect of treating abscesses in mice.

According to the difference of composition structure of the cell wall, bacteria can be divided into Gram-positive and Gram-negative bacteria, and they also resistant to a variety of antibiotics because of the cell wall. However, this peptide has a good effect against Gram-positive bacteria and Gram-negative bacteria. Flarebio offers recombinant proteins of good quality such as recombinant CDH2.